These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7906926)

  • 1. Inhibitory effect of levocabastine on allergen-induced increase of nasal reactivity to histamine and cell influx.
    Pazdrak K; Górski P; Ruta U
    Allergy; 1993 Nov; 48(8):598-601. PubMed ID: 7906926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of topical levocabastine on nasal response to allergen challenge and nasal hyperreactivity in perennial rhinitis.
    de Graaf-in 't Veld T; Garrelds IM; van Toorenenbergen AW; Mulder PG; Gerth van Wijk R; Boegheim JP
    Ann Allergy Asthma Immunol; 1995 Sep; 75(3):261-6. PubMed ID: 7552929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis.
    Svensson C; Andersson M; Greiff L; Blychert LO; Persson CG
    Allergy; 1998 Apr; 53(4):367-74. PubMed ID: 9574878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eosinophil cationic protein (ECP) and tryptase in the nasal lavage fluid (NLF) of children with grass pollen rhinitis: levocabastine effect.
    Bernardini R; Novembre E; Mugnaini L; Rossi ME; Vierucci A
    Allergy Asthma Proc; 1998; 19(2):75-80. PubMed ID: 9578915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of topical treatment with H1 and H2 antagonists on clinical symptoms and nasal vascular reactions in patients with allergic rhinitis.
    Holmberg K; Pipkorn U; Bake B; Blychert LO
    Allergy; 1989 May; 44(4):281-7. PubMed ID: 2567579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levocabastine: a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis.
    Janssens MM
    Rhinol Suppl; 1992 Sep; 13():39-49. PubMed ID: 1358140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis.
    Janssens MM; Vanden Bussche G
    Clin Exp Allergy; 1991 May; 21 Suppl 2():29-36. PubMed ID: 1680536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test.
    Pécoud A; Zuber P; Kolly M
    Int Arch Allergy Appl Immunol; 1987; 82(3-4):541-3. PubMed ID: 2883132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal levocabastine provides fast and effective protection from nasal allergen challenge.
    Bachert C; Wagenmann M; Vossen-Holzenkamp S
    Rhinology; 1996 Sep; 34(3):140-3. PubMed ID: 8938880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of levocabastine nasal spray in nasal provocation tests.
    Palma-Carlos AG; Palma-Carlos ML; Rombaut N
    Int J Clin Pharmacol Res; 1988; 8(1):25-30. PubMed ID: 2896636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of levocabastine and furosemide pretreatment on hyperreactive response after nasal provocation with hypotonic aerosol in subjects with allergic rhinitis.
    Anzic SA; Dzepina D; Kalogjera L
    Eur Arch Otorhinolaryngol; 2007 Nov; 264(11):1309-14. PubMed ID: 17618447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of loratadine and terfenadine on the induced nasal allergic reaction.
    Baroody FM; Lim MC; Proud D; Kagey-Sobotka A; Lichtenstein LM; Naclerio RM
    Arch Otolaryngol Head Neck Surg; 1996 Mar; 122(3):309-16. PubMed ID: 8607960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimentally induced nasal hypersecretion does not reduce the efficacy of intranasal levocabastine.
    Borum S; Nielsen K; Bisgaard H; Mygind N
    Rhinology; 1998 Dec; 36(4):153-5. PubMed ID: 9923056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological and clinical properties of levocabastine hydrochloride (eye drop and nasal spray), a selective H1 antagonist].
    Akiyoshi M; Shigeoka T; Torii S; Maki E; Enomoto S; Takahashi H; Hirano F
    Nihon Yakurigaku Zasshi; 2002 Mar; 119(3):175-84. PubMed ID: 11915520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions.
    Corren J; Rachelefsky G; Spector S; Schanker H; Siegel S; Holton D; Karcher K; Travers S
    J Allergy Clin Immunol; 1999 Apr; 103(4):574-80. PubMed ID: 10200003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of levocabastine, a new selective H1-receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen.
    Kolly M; Pécoud A
    Br J Clin Pharmacol; 1986 Oct; 22(4):389-94. PubMed ID: 2876723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical levocabastine for the treatment of perennial allergic rhinitis.
    Elwany S; Bassiouny M
    J Laryngol Otol; 1997 Oct; 111(10):935-40. PubMed ID: 9425481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cetirizine on substance P release in patients with perennial allergic rhinitis.
    Shirasaki H; Watanabe K; Kanaizumi E; Sato J; Konno N; Narita S; Himi T
    Ann Otol Rhinol Laryngol; 2004 Dec; 113(12):941-5. PubMed ID: 15633894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ipratropium on nasal reactivity to histamine and eosinophil influx in perennial allergic rhinitis.
    Górski P; Pazdrak K; Ruta U
    Eur J Clin Pharmacol; 1993; 44(6):545-7. PubMed ID: 8405010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.
    Dechant KL; Goa KL
    Drugs; 1991 Feb; 41(2):202-24. PubMed ID: 1709851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.